ஒருங்கிணைந்த ப்ரிபரேஶந்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஒருங்கிணைந்த ப்ரிபரேஶந்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஒருங்கிணைந்த ப்ரிபரேஶந்ஸ் Today - Breaking & Trending Today

Why the Immutep (ASX:IMM) share price rocketed 14% today

Why the Immutep (ASX:IMM) share price rocketed 14% today
Why the Immutep (ASX:IMM) share price rocketed 14% today
The biotech company’s shares had a stellar day on the back of an intellectual property deal. Here are the details.
Aaron Teboneras has been a Motley Fool contributor since early August 2020. After graduating from RMIT University with a Business degree, Aaron spent most of his years either travelling or working in various industries. Aaron’s most notable appointments include National Australia Bank, and Computershare where he discovered his passion for the Australian sharemarket. Outside of researching and writing for Motley Fool, Aaron enjoys trekking on adventures across the world and learning new life skills. ....

United States , Xiaoming Zou , Frederic Triebel , Immutep Ltd , Chinese Patent Office , Combined Preparations , ஒன்றுபட்டது மாநிலங்களில் , சீன காப்புரிமை அலுவலகம் , ஒருங்கிணைந்த ப்ரிபரேஶந்ஸ் ,

Why the Immutep (ASX:IMM) share price will be in focus today

Why the Immutep (ASX:IMM) share price will be in focus today
fool.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com.au Daily Mail and Mail on Sunday newspapers.

United States , Scott Phillips , Marc Voigt , Immutep Ltd , United States Patent Trade Mark Office , United States Patent , Combined Preparations , Motley Fool Share Advisor , ஒன்றுபட்டது மாநிலங்களில் , ஸ்காட் பிலிப்ஸ் , மார்க் வாய்க்ட் , ஒன்றுபட்டது மாநிலங்களில் காப்புரிமை வர்த்தகம் குறி அலுவலகம் , ஒன்றுபட்டது மாநிலங்களில் காப்புரிமை , ஒருங்கிணைந்த ப்ரிபரேஶந்ஸ் ,

What's with the Immutep (ASX:IMM) share price today?

Interim data
Immutep reported that interim data from the TACTI-002 study was encouraging. Subsequently, while at the Society for Immunotherapy of Cancer, the company mentioned the second line HNSCC patient data was very robust and formed a basis for additional clinical development.
Lastly, Immutep notified the market that the TACTI-002 trial involving patients with first-line non-small cell lung cancer (NSCLC) had commenced. An additional 4 new patients have also been recruited, on top of the already 74 patients that were previously announced on 19 November. 40 of the 110 patients with first-line NSCLC have now been recruited for Part A of the TACTI-002 study.
The company expects further interim data from the TACTI-002 study in the first half of 2021. ....

United States , New South Wales , Scott Phillips , Immutep Ltd , Society For Immunotherapy Of Cancer , United States Patent Trade Mark Office , United States Patent , Trademark Office , Combined Preparations , Motley Fool Share Advisor , ஒன்றுபட்டது மாநிலங்களில் , புதியது தெற்கு வேல்ஸ் , ஸ்காட் பிலிப்ஸ் , சமூகம் க்கு நோயெதிர்ப்பு சிகிச்சை ஆஃப் புற்றுநோய் , ஒன்றுபட்டது மாநிலங்களில் காப்புரிமை வர்த்தகம் குறி அலுவலகம் , ஒன்றுபட்டது மாநிலங்களில் காப்புரிமை , முத்திரை அலுவலகம் , ஒருங்கிணைந்த ப்ரிபரேஶந்ஸ் ,